Logo image of DNTH

DIANTHUS THERAPEUTICS INC (DNTH) Stock Fundamental Analysis

NASDAQ:DNTH - Nasdaq - US2528281080 - Common Stock - Currency: USD

17.53  +0.14 (+0.81%)

After market: 17.53 0 (0%)

Fundamental Rating

3

Overall DNTH gets a fundamental rating of 3 out of 10. We evaluated DNTH against 558 industry peers in the Biotechnology industry. DNTH has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, DNTH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNTH had negative earnings in the past year.
DNTH had a negative operating cash flow in the past year.
DNTH had negative earnings in each of the past 5 years.
In the past 5 years DNTH always reported negative operating cash flow.
DNTH Yearly Net Income VS EBIT VS OCF VS FCFDNTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -28.90%, DNTH is doing good in the industry, outperforming 67.74% of the companies in the same industry.
The Return On Equity of DNTH (-30.65%) is better than 77.06% of its industry peers.
Industry RankSector Rank
ROA -28.9%
ROE -30.65%
ROIC N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
DNTH Yearly ROA, ROE, ROICDNTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DNTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNTH Yearly Profit, Operating, Gross MarginsDNTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

DNTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNTH has more shares outstanding than it did 1 year ago.
DNTH has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNTH Yearly Shares OutstandingDNTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DNTH Yearly Total Debt VS Total AssetsDNTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

DNTH has an Altman-Z score of 15.90. This indicates that DNTH is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.90, DNTH belongs to the best of the industry, outperforming 92.29% of the companies in the same industry.
DNTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.9
ROIC/WACCN/A
WACC9.47%
DNTH Yearly LT Debt VS Equity VS FCFDNTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 15.99 indicates that DNTH has no problem at all paying its short term obligations.
DNTH's Current ratio of 15.99 is amongst the best of the industry. DNTH outperforms 89.25% of its industry peers.
DNTH has a Quick Ratio of 15.99. This indicates that DNTH is financially healthy and has no problem in meeting its short term obligations.
DNTH has a better Quick ratio (15.99) than 89.25% of its industry peers.
Industry RankSector Rank
Current Ratio 15.99
Quick Ratio 15.99
DNTH Yearly Current Assets VS Current LiabilitesDNTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.60% over the past year.
Looking at the last year, DNTH shows a very strong growth in Revenue. The Revenue has grown by 76.28%.
EPS 1Y (TTM)50.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.85%
Revenue 1Y (TTM)76.28%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%33.07%

3.2 Future

Based on estimates for the next years, DNTH will show a decrease in Earnings Per Share. The EPS will decrease by -5.99% on average per year.
DNTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 104.19% yearly.
EPS Next Y-30.93%
EPS Next 2Y-19.27%
EPS Next 3Y-16.81%
EPS Next 5Y-5.99%
Revenue Next Year-41.8%
Revenue Next 2Y-29.1%
Revenue Next 3Y22.14%
Revenue Next 5Y104.19%

3.3 Evolution

DNTH Yearly Revenue VS EstimatesDNTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DNTH Yearly EPS VS EstimatesDNTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNTH Price Earnings VS Forward Price EarningsDNTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNTH Per share dataDNTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

A cheap valuation may be justified as DNTH's earnings are expected to decrease with -16.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.27%
EPS Next 3Y-16.81%

More info and screens

0

5. Dividend

5.1 Amount

DNTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIANTHUS THERAPEUTICS INC

NASDAQ:DNTH (6/2/2025, 8:00:01 PM)

After market: 17.53 0 (0%)

17.53

+0.14 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06
Inst Owners119.34%
Inst Owner Change6.49%
Ins Owners0.02%
Ins Owner Change0%
Market Cap563.76M
Analysts87.78
Price Target50.09 (185.74%)
Short Float %21.5%
Short Ratio19.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.99%
Min EPS beat(2)5.31%
Max EPS beat(2)6.67%
EPS beat(4)3
Avg EPS beat(4)-0.43%
Min EPS beat(4)-22.05%
Max EPS beat(4)8.35%
EPS beat(8)5
Avg EPS beat(8)-59.88%
EPS beat(12)7
Avg EPS beat(12)-40.97%
EPS beat(16)9
Avg EPS beat(16)-30.44%
Revenue beat(2)2
Avg Revenue beat(2)27.84%
Min Revenue beat(2)13.92%
Max Revenue beat(2)41.76%
Revenue beat(4)4
Avg Revenue beat(4)187.49%
Min Revenue beat(4)13.92%
Max Revenue beat(4)465.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.63%
EPS NQ rev (1m)3.82%
EPS NQ rev (3m)6.4%
EPS NY rev (1m)1.91%
EPS NY rev (3m)3.31%
Revenue NQ rev (1m)-1.1%
Revenue NQ rev (3m)-5.77%
Revenue NY rev (1m)-8.17%
Revenue NY rev (3m)-13.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 86.41
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-2.88
EYN/A
EPS(NY)-3.7
Fwd EYN/A
FCF(TTM)-2.83
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0.2
BVpS10.22
TBVpS10.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.9%
ROE -30.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.04%
Cap/Sales 1.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.99
Quick Ratio 15.99
Altman-Z 15.9
F-Score3
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)96.54%
Cap/Depr(5y)74.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.85%
EPS Next Y-30.93%
EPS Next 2Y-19.27%
EPS Next 3Y-16.81%
EPS Next 5Y-5.99%
Revenue 1Y (TTM)76.28%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%33.07%
Revenue Next Year-41.8%
Revenue Next 2Y-29.1%
Revenue Next 3Y22.14%
Revenue Next 5Y104.19%
EBIT growth 1Y-245.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.55%
OCF growth 3YN/A
OCF growth 5YN/A